Login to Your Account

Novartis strikes $170M pact with Surface Oncology

By Michael Fitzhugh
Staff Writer

Monday, January 11, 2016

SAN FRANCISCO – Novartis AG moved to expand its immuno-oncology pipeline Monday through a strategic alliance and licensing agreement with Cambridge, Mass.-based Surface Oncology Inc. worth up to $170 million in up-front, equity and near-term milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription